hotspot -WSS

hotspot

author：explore 2025-09-06 04:37:02 - browse：7357

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： New study raises questions about niacin and heart health

WSS

New CMS data security rules will hurt Medicare, Medicaid research

Weight loss drugs aren’t covered by Obamacare. That may change

Hospitals are piloting generative AI tools as regulators play catch

Abridge raises $150m as clinical notes automation market heats up

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

explore

hotspot

focus

The high cost of giving birth even with insurance

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

ChatGPT in medicine: STAT answers readers' burning questions

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Opioid cravings were reduced by anti

Peter Hotez and the public health issue of online harassment

STAT Virtual Event: ASCO Recap, Live!

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

explore

California wildfire smoke linked to 52,000 early deaths, study says

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

WATCH: Why do our ears pop?

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Congress may force more Covid

New study raises questions about niacin and heart health

leisure time

entertainment

entertainment

hotspot